<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="709">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967706</url>
  </required_header>
  <id_info>
    <org_study_id>ZRHM-PK-05-JP</org_study_id>
    <secondary_id>ZRHM-PK-05-JP</secondary_id>
    <nct_id>NCT01967706</nct_id>
  </id_info>
  <brief_title>Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).</brief_title>
  <official_title>A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile and Safety of Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) Following Single Use in Smoking, Healthy Subjects Compared to Menthol Conventional Cigarettes and Nicotine Gum.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile
      (rate and amount of nicotine absorbed) following a single use of the THS 2.2 Menthol (mTHS)
      compared to the PK profiles from a single use of a menthol conventional cigarette (mCC) and
      from a single use of nicotine replacement therapy gum (NRT).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Ratios of the Maximum Concentration (Cmax) of Nicotine Following Single Use of mTHS, mCC and NRT</measure>
    <time_frame>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The ratios mTHS:mCC and mTHS:NRT of Cmax takes into consideration the blood measurements taken at both Day 1 (mTHS) and Day 3 (mCC, NRT) for the sequences &quot;mTHS then mCC&quot; and &quot;mTHS then NRT&quot;, and Day 1 (mCC, NRT) and Day 3 (mTHS) for the sequences &quot;mCC then mTHS&quot; and &quot;NRT then mTHS&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of the Area Under the Plasma Concentration Versus Time Curve From Time Zero (Pre-product Use) to Last Time Point [AUC(0-last)] Following Single Use of mTHS, mCC and NRT</measure>
    <time_frame>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The ratios mTHS:mCC and mTHS:NRT of AUC(0-last) takes into consideration the blood measurements taken at both Day 1 (mTHS) and Day 3 (mCC, NRT) for the sequences &quot;mTHS then mCC&quot; and &quot;THS then NRT&quot;, and Day 1 (mCC, NRT) and Day 3 (mTHS) for the sequences &quot;mCC then mTHS&quot; and &quot;NRT then mTHS&quot;.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>mTHS then mCC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of mTHS)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of mCC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mCC then mTHS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of mCC)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of mTHS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mTHS then NRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of mTHS)
Day 2 = wash-out
Day 3 = 2nd intervention (single administration of NRT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRT then mTHS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single administration of NRT)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of mTHS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mTHS</intervention_name>
    <description>Single use of Tobacco Heating System 2.2 Menthol (mTHS)</description>
    <arm_group_label>mTHS then mCC</arm_group_label>
    <arm_group_label>mCC then mTHS</arm_group_label>
    <arm_group_label>mTHS then NRT</arm_group_label>
    <arm_group_label>NRT then mTHS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mCC</intervention_name>
    <description>Single use of subject's own menthol conventional cigarette (mCC)</description>
    <arm_group_label>mTHS then mCC</arm_group_label>
    <arm_group_label>mCC then mTHS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NRT</intervention_name>
    <description>Single administration of 2 mg gum (Nicorette ® 2mg)</description>
    <arm_group_label>mTHS then NRT</arm_group_label>
    <arm_group_label>NRT then mTHS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is Japanese.

          -  Smoking, healthy subject as judged by the Investigator.

          -  Subject has smoked at least 10 commercially available mCCs per day (no brand
             restrictions) for the last 4 weeks.

          -  Subject has smoked for at least the last 3 consecutive years.

          -  Subject does not plan to quit smoking in the next 3 months.

        Exclusion Criteria:

          -  As per Investigator judgment, the subject cannot participate in the study for any
             reason (e.g., medical, psychiatric, and/or social reason).

          -  Subject has received medication within 14 days or within 5 half-lives of a medication
             (whichever is longer) which has an impact on CYP2A6 activity.

          -  Female subject is pregnant or breast feeding.

          -  Female subject does not agree to use an acceptable method of effective contraception.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fumimasa Nobuoka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ageo Medical Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ageo Medical Clinic, 3133 Haraichi, Ageo-shi</name>
      <address>
        <city>Saitama</city>
        <zip>362 0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 29, 2015</lastchanged_date>
  <firstreceived_date>October 18, 2013</firstreceived_date>
  <firstreceived_results_date>June 10, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Nicotine absorption</keyword>
  <keyword>Modified risk tobacco product</keyword>
  <keyword>Conventional cigarette</keyword>
  <keyword>Nicotine replacement therapy</keyword>
  <keyword>Nicotine gum</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Menthol</mesh_term>
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study initiated (first subject screened): 01 August 2013
At admission (Day -1), all the subjects performed a product trial (Tobacco Sticks and subsequently NRT gum).
From enrollment, they were asked to remain abstinent from smoking for at least 24 hours (Day 0) before being randomized on Day 1 into 1 of the 4 sequences.</recruitment_details>
      <pre_assignment_details>Enrolled population = 73 subjects: 11 exposed to mTHS and NRT at Admission but not randomized and 62 randomized as described below:
Sequence &quot;mTHS then mCC&quot;: 22 subjects
Sequence &quot;mCC then mTHS&quot;: 22 subjects
Sequence &quot;mTHS then NRT&quot;: 9 subjects
Sequence &quot;NRT then mTHS&quot;: 9 subjects</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>mTHS Then mCC</title>
          <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of mTHS)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of mCC).</description>
        </group>
        <group group_id="P2">
          <title>mCC Then mTHS</title>
          <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of mCC)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of mTHS).</description>
        </group>
        <group group_id="P3">
          <title>mTHS Then NRT</title>
          <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of mTHS)
Day 2 = wash-out
Day 3 = 2nd intervention (single administration of NRT)</description>
        </group>
        <group group_id="P4">
          <title>NRT Then mTHS</title>
          <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single administration of NRT)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of mTHS).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Washout Period of 1 Day (Day 0)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>First Intervention (Day 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period of 1 Day (Day 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (Day 3)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>PK population: all randomized subjects who completed at least 1 of the single-use days, with at least 1 derived PK parameter. Subjects with major protocol deviations impacting the evaluation of the results were excluded.
62 randomized subjects : 44 in Group 1, 18 in Group 2.
61 completers: 43 in Group 1 (1 withdrawn subject), 18 in Group 2.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>This population comprises the following sequences:
Sequence &quot;mTHS then mCC&quot;
Sequence &quot;mCC then mTHS&quot;</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>This population comprises the following sequences:
Sequence &quot;mTHS then NRT&quot;
Sequence &quot;NRT then mTHS&quot;</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="43"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="61"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <sub_title>Between 23 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33.4" spread="10.03"/>
                <measurement group_id="B2" value="30.7" spread="7.80"/>
                <measurement group_id="B3" value="32.6" spread="9.44"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="29"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>International Organization for Standardization (ISO) nicotine level</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>≤ 0.6 mg</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt; 0.6 to ≤ 1 mg</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ratios of the Maximum Concentration (Cmax) of Nicotine Following Single Use of mTHS, mCC and NRT</title>
        <description>The ratios mTHS:mCC and mTHS:NRT of Cmax takes into consideration the blood measurements taken at both Day 1 (mTHS) and Day 3 (mCC, NRT) for the sequences &quot;mTHS then mCC&quot; and &quot;mTHS then NRT&quot;, and Day 1 (mCC, NRT) and Day 3 (mTHS) for the sequences &quot;mCC then mTHS&quot; and &quot;NRT then mTHS&quot;.</description>
        <time_frame>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Ratio mTHS:mCC =&gt; Group 1, sequences &quot;mTHS then mCC&quot; (21 subjects + 1 voluntary withdrawal) + &quot;mCC then mTHS&quot; (22 subjects)
Ratio mTHS:NRT =&gt; Group 2, sequences &quot;mTHS then NRT&quot; (9 subjects) + &quot;NRT then mTHS&quot; (9 subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Ratio mTHS:mCC</title>
            <description>This population comprises the following sequences:
Sequence &quot;mTHS then mCC&quot;
Sequence &quot;mCC then mTHS&quot;</description>
          </group>
          <group group_id="O2">
            <title>Ratio mTHS:NRT</title>
            <description>This population comprises the following sequences:
Sequence &quot;mTHS then NRT&quot;
Sequence &quot;NRT then mTHS&quot;</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Ratios of the Maximum Concentration (Cmax) of Nicotine Following Single Use of mTHS, mCC and NRT</title>
            <description>The ratios mTHS:mCC and mTHS:NRT of Cmax takes into consideration the blood measurements taken at both Day 1 (mTHS) and Day 3 (mCC, NRT) for the sequences &quot;mTHS then mCC&quot; and &quot;mTHS then NRT&quot;, and Day 1 (mCC, NRT) and Day 3 (mTHS) for the sequences &quot;mCC then mTHS&quot; and &quot;NRT then mTHS&quot;.</description>
            <units>percentage of [ng/mL]</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="88.5" lower_limit="68.6" upper_limit="114.0"/>
                  <measurement group_id="O2" value="101.63" lower_limit="62.21" upper_limit="166.04"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of the Area Under the Plasma Concentration Versus Time Curve From Time Zero (Pre-product Use) to Last Time Point [AUC(0-last)] Following Single Use of mTHS, mCC and NRT</title>
        <description>The ratios mTHS:mCC and mTHS:NRT of AUC(0-last) takes into consideration the blood measurements taken at both Day 1 (mTHS) and Day 3 (mCC, NRT) for the sequences &quot;mTHS then mCC&quot; and &quot;THS then NRT&quot;, and Day 1 (mCC, NRT) and Day 3 (mTHS) for the sequences &quot;mCC then mTHS&quot; and &quot;NRT then mTHS&quot;.</description>
        <time_frame>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Ratio mTHS:mCC =&gt; Group 1, sequences &quot;mTHS then mCC&quot; (21 subjects + 1 voluntary withdrawal) + &quot;mCC then mTHS&quot; (22 subjects)
Ratio mTHS:NRT =&gt; Group 2, sequences &quot;mTHS then NRT&quot; (9 subjects) + &quot;NRT then mTHS&quot; (9 subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Ratio mTHS:mCC</title>
            <description>This population comprises the following sequences:
Sequence &quot;mTHS then mCC&quot;
Sequence &quot;mCC then mTHS&quot;.</description>
          </group>
          <group group_id="O2">
            <title>Ratio mTHS:NRT</title>
            <description>This population comprises the following sequences:
Sequence &quot;mTHS then NRT&quot;
Sequence &quot;NRT then mTHS&quot;</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Ratio of the Area Under the Plasma Concentration Versus Time Curve From Time Zero (Pre-product Use) to Last Time Point [AUC(0-last)] Following Single Use of mTHS, mCC and NRT</title>
            <description>The ratios mTHS:mCC and mTHS:NRT of AUC(0-last) takes into consideration the blood measurements taken at both Day 1 (mTHS) and Day 3 (mCC, NRT) for the sequences &quot;mTHS then mCC&quot; and &quot;THS then NRT&quot;, and Day 1 (mCC, NRT) and Day 3 (mTHS) for the sequences &quot;mCC then mTHS&quot; and &quot;NRT then mTHS&quot;.</description>
            <units>percentage of [ng*h/mL]</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98.1" lower_limit="80.6" upper_limit="119.5"/>
                  <measurement group_id="O2" value="55.87" lower_limit="38.36" upper_limit="81.36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From insent consent form (ICF) signature until the end of the safety follow-up period (7 days after discharge of the subject).</time_frame>
      <desc>The safety was assessed in the safety population, consisting of 73 subjects: 62 randomized subjects (44 in Group 1, 18 in Group 2) and 11 subjects exposed to mTHS and NRT from the product trials on Day -1 but not randomized.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>This population comprises the following sequences:
Sequence &quot;mTHS then mCC&quot;
Sequence &quot;mCC then mTHS&quot;</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>This population comprises the following sequences:
Sequence &quot;mTHS then NRT&quot;
Sequence &quot;NRT then mTHS&quot;</description>
        </group>
        <group group_id="E3">
          <title>Enrolled But Not Randomized</title>
          <description>Subjects who tried the mTHS at Admission (Day -1) but were not randomized in 1 of the 2 groups as they were back-up subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>We confirm we have the contractual provisions in place which specifies that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.
The Intellectual Property rights and research results from the present study belongs to the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christelle HAZIZA</name_or_title>
      <organization>Philip Morris Products S.A.</organization>
      <phone>+41 (58) 242 2625</phone>
      <email>Christelle.Haziza@pmi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
